ATE205092T1 - Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe - Google Patents

Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Info

Publication number
ATE205092T1
ATE205092T1 AT93101237T AT93101237T ATE205092T1 AT E205092 T1 ATE205092 T1 AT E205092T1 AT 93101237 T AT93101237 T AT 93101237T AT 93101237 T AT93101237 T AT 93101237T AT E205092 T1 ATE205092 T1 AT E205092T1
Authority
AT
Austria
Prior art keywords
optionally substituted
derivative
highly water
soluble cyclodextrin
group
Prior art date
Application number
AT93101237T
Other languages
English (en)
Inventor
Yoshihiro Ohmachi
Yoshihiro Tsugawa
Akihiro Nagai
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE205092T1 publication Critical patent/ATE205092T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT93101237T 1992-01-30 1993-01-28 Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe ATE205092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1523692 1992-01-30
JP33202192 1992-12-11

Publications (1)

Publication Number Publication Date
ATE205092T1 true ATE205092T1 (de) 2001-09-15

Family

ID=26351355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93101237T ATE205092T1 (de) 1992-01-30 1993-01-28 Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Country Status (5)

Country Link
US (1) US5536623A (de)
EP (1) EP0555693B1 (de)
AT (1) ATE205092T1 (de)
CA (1) CA2088428A1 (de)
DE (1) DE69330690T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
EP2317845A4 (de) * 2008-07-18 2011-11-09 Zafgen Inc Verfahren zur behandlung einer übergewichtigen oder fettleibigen person
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (de) 2012-05-08 2018-08-15 Zafgen, Inc. Behandlung von hypothalamischer fettsucht mit metap2-inhibitoren
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN113321753B (zh) * 2021-05-19 2022-08-30 山东滨州智源生物科技有限公司 多元糖基氨基酸基环糊精衍生物、水凝胶的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
ES2059571T3 (es) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
EP0335545B2 (de) * 1988-03-29 1998-09-23 University Of Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP1004318A3 (de) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Zyklodextrin-zusammensetzung

Also Published As

Publication number Publication date
CA2088428A1 (en) 1993-07-31
DE69330690D1 (de) 2001-10-11
DE69330690T2 (de) 2002-06-20
EP0555693A1 (de) 1993-08-18
EP0555693B1 (de) 2001-09-05
US5536623A (en) 1996-07-16

Similar Documents

Publication Publication Date Title
DE69330690D1 (de) Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
DE69124715D1 (de) Zyklodextrinkomplex
ATE71090T1 (de) Heterocyclische verbindungen und deren herstellung und verwendung.
DE68923274D1 (de) Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
JP3673888B2 (ja) ポルフィリン類金属錯体の製造方法
ATE145209T1 (de) Tri-aza-makrocyclen und verfahren zu ihrer herstellung
ATE138571T1 (de) Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
HUP0102599A2 (hu) Artemizinin-származékok, eljárás a vegyületek előállítására, és a vegyületeket tartalmazó gyógyszerészeti készítmények
Lydon et al. Synthesis and characterization of coordinated disulfides. Single-crystal structural analysis of [(en) 2Co (S (SC (CH3) 2COOH) C (CH3) 2COO)](ClO4) 2. cntdot. H2O
DE69013528D1 (de) Eine Perfluoralkylgruppe enthaltende Verbindung.
DE3885115D1 (de) Verfahren zur Herstellung von Thiolen.
RO92245A (ro) Procedeu pentru prepararea unor derivati de 1,6-naftiridina
DE69019294D1 (de) Triazolyl-Hydrazidderivate und Verfahren zu ihrer Herstellung.
KR880001645A (ko) 치료적으로 유용한 프리스티나마이신의 제조방법
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
HU895522D0 (en) Process for the preparation of new thienyl-oxy-alkyl-amine derivatives and pharmaceutical compositions containing them
KR890000406A (ko) 신나모일아미드 유도체, 그들의 제조방법, 그들을 함유하는 제약학적 조성물 및 그들의 사용
Santos et al. Siderophore analogues. Chelating properties of a new cyclic diazadihydroxamic acid
KR900014305A (ko) 소염제로서의 나프탈렌메탄아미노 유도체의 용도 및 이를 함유한 약학 조성물
Elliott et al. Pentaammineruthenium (II/III) imidazole and imidazolate complexes of 2-carboxylatoimidazolate and 2-imidazolecarboxaldehyde
SE9802643L (sv) 2,3-Disubstituerade cyklopentanonderivat, förfarande för framställning av den och medicinsk användning därav
KR870001223A (ko) 포스페이트 에스테르 유도체의 제조방법
KR910006238A (ko) 피라즐-3-카르복스아미드
AR008257A1 (es) Poliamidas estables a la intemperie y procedimiento para su elaboracion y aplicacion
IL106692A (en) AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING